BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35551405)

  • 1. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
    Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
    J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
    Jo J; Donahue J; Sarai G; Petroni G; Schiff D
    Neuro Oncol; 2022 Mar; 24(3):455-464. PubMed ID: 34383073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: A meta-analysis.
    Yang J; He Z; Li M; Hong T; Ouyang T
    J Stroke Cerebrovasc Dis; 2023 Aug; 32(8):107243. PubMed ID: 37413715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.
    Leader A; Hamulyák EN; Carney BJ; Avrahami M; Knip JJ; Rozenblatt S; Beenen LFM; Yust-Katz S; Icht O; Coppens M; Raanani P; Middeldorp S; Büller HR; Zwicker JI; Spectre G
    Blood Adv; 2020 Dec; 4(24):6291-6297. PubMed ID: 33351124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
    Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
    J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
    Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
    Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases.
    Abdelmessih E; Ahuja T; Wo S; Sango A; Papadopoulos J; Green D; Xiang E
    J Thromb Thrombolysis; 2024 Mar; 57(3):418-427. PubMed ID: 38281232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis.
    Rojas-Hernandez CM; Oo TH; García-Perdomo HA
    J Thromb Thrombolysis; 2017 Feb; 43(2):233-240. PubMed ID: 27704333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
    Wang TF; Grubic N; Carrier M; Canney M; Delluc A; Hundemer GL; Knoll G; Lazo-Langner A; Massicotte-Azarniouch D; Tanuseputro P; Sood MM
    Am J Hematol; 2023 Sep; 98(9):1374-1382. PubMed ID: 37340812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
    Iyengar V; Agrawal S; Chiasakul T; Tehranchi K; Mcnichol M; Carney BJ; Leader A; Zwicker JI; Patell R
    J Thromb Haemost; 2024 Feb; 22(2):423-429. PubMed ID: 37866517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
    Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
    J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs.
    Poli D; Antonucci E; Vignini E; Martinese L; Testa S; Simioni P; Pengo V; Pignatelli P; Falanga A; Masciocco L; Barcellona D; Ciampa A; Chiarugi P; Paparo C; Ageno W; Palareti G;
    Eur J Intern Med; 2020 Oct; 80():73-77. PubMed ID: 32522446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A; Williams H; Baer MR; Zimrin AB; Law JY
    Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
    Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
    J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.